Amneal Pharmaceuticals, Inc. (AMRX) 股票分析

公司概述

Amneal Pharmaceuticals, Inc. operates as a global biopharmaceutical entity dedicated to the development, manufacturing, marketing, and distribution of generic, injectable, biosimilar, and specialty branded pharmaceutical products across the United States, India, Ireland, and international markets. The company functions within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, positioning it as a key player in providing accessible pharmaceutical solutions. In terms of scale, Amneal Pharmaceuticals holds a market capitalization of $4.08B and reports annual revenue of $3.02B, supported by an employee base of 8,700 individuals. These financial dimensions indicate that the company maintains a substantial operational footprint within the specialty and generic drug manufacturing landscape, reflecting a significant presence that allows for diversified product offerings and global reach.

财务健康

The company reported revenue of $3.02B and EBITDA of $644.27M over the trailing twelve months, while net income stood at $72.06M. The substantial gap between the $3.02B revenue figure and the $72.06M net income reveals a cost structure where operating expenses, including cost of goods sold and general administrative costs, consume a significant portion of top-line growth, leaving a relatively thin profit margin. Despite this, the firm generated free cash flow of $197.07M, which provides a critical measure of financial flexibility by indicating the ability to fund operations, service debt, or pursue strategic initiatives without relying solely on external financing. The gross margin stands at 37.4%, suggesting a moderate pricing power or cost efficiency in manufacturing; however, the operating margin of 14.1% and profit margin of 2.4% further illustrate the pressure on profitability typical in the generic pharmaceutical space. On the balance sheet, total cash of $286.47M is significantly lower than total debt of $2.69B, and the debt-to-equity ratio is exceptionally high at 45095.52, indicating a highly leveraged capital structure rather than a conservative one. Liquidity is assessed via a current ratio of 2.17, which suggests the company possesses more than double the current assets needed to cover short-term liabilities. Return on equity is listed as N/A, while return on assets is 7.3%, providing a view of asset utilization efficiency even in the absence of a traditional equity return metric.

估值评估

Valuation metrics show a trailing P/E ratio of 58.18 compared to a forward P/E of 10.88, implying that the market currently prices earnings at a premium that expects a dramatic contraction in future earnings or a significant shift in profitability that would bring the multiple down. The price-to-book ratio is recorded at -56.89, a negative figure that typically indicates the company's book value is negative due to accumulated debt exceeding assets, suggesting the market is pricing the firm based on intangible value or future cash flows rather than tangible book equity. Alternative metrics include a price-to-sales ratio of 1.35 and an EV/EBITDA of 10.10, which suggest the stock is trading at a moderate multiple of sales relative to its earnings before interest, taxes, depreciation, and amortization. The 52-week high is $15.42 and the 52-week low is $6.68, placing the current trading range within a wide band that reflects high volatility typical of high-beta stocks. With a beta of 1.32, the stock exhibits price volatility that is 32% higher than the broader market, indicating that it is more sensitive to systemic market movements than large-cap benchmark indices.

Growth & Income

Revenue growth year-over-year is recorded at 11.5%, while earnings growth is listed as N/A, indicating that top-line expansion is currently outpacing bottom-line realization due to the low profit margins discussed in the financial health section. The company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all net income is retained within the business rather than distributed to shareholders. This reinvestment strategy aligns with the company's need to service its high debt load and potentially fund operational efficiencies or acquisitions in the specialty drug sector. The overall growth and income profile is characterized by solid revenue expansion and zero dividend yield, focusing capital retention to support a highly leveraged balance sheet in a competitive generic pharmaceutical market.